Stock LYRA LYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
4.03 USD -12.96% Intraday chart for Lyra Therapeutics, Inc. -22.05% -23.09%
04-30 Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-19 Lyra Therapeutics, Inc. Announces Board Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Lyra Therapeutics, Inc. Announces Board Changes
CI
Lyra Therapeutics Files $300 Million Mixed Shelf Offering
MT
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics to Participate in Upcoming Investor Conferences
AQ
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer
AQ
Lyra Therapeutics, Inc Announces Appointment of Ronan O?Brien as Chief Legal Officer
CI
BTIG Assumes Lyra Therapeutics at Buy With $15 Price Target
MT
BofA Securities Increases Price Target on Lyra Therapeutics to $15 From $13, Maintains Buy Rating
MT
Lyra Therapeutics Says Phase 2 Trial for Chronic Rhinosinusitis Treatment Meets Primary Endpoint
MT
Transcript : Lyra Therapeutics, Inc. - Special Call
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
AQ
Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery
CI
Lyra Therapeutics to Participate in Upcoming Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYRA Stock
  4. News Lyra Therapeutics, Inc.